wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38853857-0C2C6626-EDBB-46BC-93F6-466561BA3644
Q38853857-0C2C6626-EDBB-46BC-93F6-466561BA3644
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38853857-0C2C6626-EDBB-46BC-93F6-466561BA3644
Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
P2860
Q38853857-0C2C6626-EDBB-46BC-93F6-466561BA3644
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38853857-0C2C6626-EDBB-46BC-93F6-466561BA3644
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6550c4c1addf04560026195ad9b9e39be8d7042a
P2860
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.